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Abstract
Background: Approximately 250 million people worldwide are chronically infected with hepatitis B virus (HBV)
and more than half of the hepatocellular carcinoma (HCC) cases are attributed to this infection. As HCC has a
high mortality rate, and current treatment options are remarkably limited, the development of new therapeutic
treatment strategies is warranted.
Methods: In this study, woodchucks infected with woodchuck hepatitis virus (WHV), and with pre-existing liver
tumors, were used as a model to investigate if complexes of cationic liposomes and non-coding DNA (JVRS-100)
were effective in treatment of HCC.
Results: It was observed that the high serum viral load that is present in a typical chronic WHV infection (i.e.,
approximately 100-fold higher than human viral loads) results in immune suppression and resistance to treatment
with JVRS-100. Treatment of woodchucks with lower serum viral load that more closely matched with the viral load
usually seen in human HBV infection appears a better model for immunotherapeutic development based on the
responsiveness to JVRS-100 treatment. In the latter case, marked declines in WHV DNA and WHV surface antigen
were determined over the 12-week treatment period and WHV markers stayed suppressed during most time points
of the 12-week follow-up period. Even more remarkably, the formation of new liver tumors was not observed in
woodchucks treated with a well-tolerated dose of JVRS-100, as compared to several new tumors that developed in
vehicle-treated control animals.
Conclusions: Although there was little decrease in the volumes of the liver tumors existing at the time of treatment, it
is generally accepted that preventing the spread and metastasis of almost always fatal cancers such as HCC and thus,
reducing it to a chronic and treatable disease can also be a successful therapeutic approach. The results in woodchucks
warrant the investigation of JVRS-100 as an intervention to prevent liver cancer in patients chronically infected with
HBV and at high risk for HCC development.
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Background
Chronic infection with hepatitis B virus (HBV) is a major
cause of hepatocellular carcinoma (HCC), which is the
fifth most common cancer in the world and the third lead-
ing cause of cancer deaths [1, 2]. HCC has a high mortal-
ity rate because it is frequently asymptomatic and the
patient does not seek medical attention until it is too late
for surgical removal [2]. Treatment options are limited as
HCC at an advanced stage does not respond well to
chemotherapy [2, 3]. Therefore, there is an urgent need
for developing new treatment strategies against HCC, in
general and against HBV-induced HCC, in particular.
Infection with HBV is a major public health problem
and is responsible for an estimated 1.2 million deaths per
year worldwide. Death is attributed in most cases to the
development of chronic liver injury, cirrhosis, and primary
HCC. Estimates are that more than 2 billion people
throughout the world have serological evidence of previ-
ous or current HBV infection and that at least 248 million
individuals are chronic carriers of HBV [4, 5]. There are
believed to be at least one million carriers in the
United States alone [6, 7]. Approved treatment strat-
egies for persistent HBV infection include the use of
(pegylated) interferon-alpha and several nucleos(t)ide
analogs, such as lamivudine, adefovir, tenofovir, telbi-
vudine, and entecavir. Less than 30% of the patients,
however, have sustained antiviral response and ad-
verse side-effects are significant [8–10]. Furthermore,
the use of current antiviral drugs is limited due to
the emergence of drug resistant variants and the risk
of relapse upon treatment discontinuation. Although
there is an efficacious prophylactic HBV vaccine, and re-
cent studies have shown that vaccination of infants signifi-
cantly reduces the development of liver cancer [11],
chronic HBV infections are on the rise as well as an
alarming increase in the incidence of liver cancer in the
United States. As a result, liver cancer is fast becoming an
increasing public health threat in the United States and
has a five-year survival rate of less than 10%, making it
one of the deadliest cancers in this country.
While antiviral treatments are able to keep viral load
at low or undetectable levels, recent studies have shown
that successfully treated patients still exhibit significant
levels of HBV-induced liver disease above those in unin-
fected individuals and that the risk of liver cancer is not
eliminated even in this cohort of patients [12]. Although
infected patients with low or undetectable viral load in
their blood system are less likely to develop liver cancer,
compared to patients with detectable viral load, these
individuals are still at a much higher risk than is the
general uninfected population [13]. Furthermore, the
emergence of HBV strains which are not effectively
neutralized by the current vaccine is also a significant
problem [14, 15].
There have been recent advances in the treatment of
HCC, such as the approval of Sorafenib, a small
molecule receptor inhibitor of several tyrosine and Raf
kinases. However, treatment benefit is modest as only
an approximately three month improvement in overall
survival is achieved [16]. Therefore, continued devel-
opment of therapeutic approaches to control HBV in-
fection and HCC occurrence is highly warranted and
an unmet medical need.
Complexes consisting of cationic/neutral lipid carrier
and non-coding DNA plasmid (CLDC; referred to here
as JVRS-100) are potent stimulants of innate immunity
[17–19]. Stimulation by JVRS-100 is mainly due to a
liposome-mediated potentiation of the mammalian in-
nate immune response to non-methylated CpG motifs
within the plasmid. Cationic liposomes facilitate endo-
cytosis and direct delivery of the plasmid DNA to the
endosomal compartment of cells. The targeted delivery
results then in increased binding of nucleic acids to
endosomally located toll-like receptors (TLRs), includ-
ing TRL9, TLR7/8, and TLR3 molecules thereby leading
to enhanced innate immune activation. Furthermore, in
vivo evidence suggests that the induction of a strong
TH1-type immune response is based in part by activa-
tion of cytolytic T lymphocytes (CTLs) and natural
killer (NK) cells and production of interleukin (IL) 12
(IL-12) and type I and II interferons [20–22] all of
which are known to be important mediators of antitu-
mor immunity. JVRS-100 administered in combination
with tumor cell lysates has efficacy against tumor pro-
gression in mouse models of cancer and in dogs with
naturally-occurring tumors and increased survival in
these animal models [23–25]. Furthermore, the com-
bination of JVRS-100 with antigen resulted in a potent
adjuvant effect as well as in robust antibody and CTL
responses to the target antigen. Based on these results,
the evaluation of antitumor effects of JVRS-100 in a
fully immunocompetent animal model of chronic HBV
infection with virus-induced HCC is warranted.
The woodchuck model of chronic HBV infection is
recognized as a valuable translational animal model for
HBV-related research [26]. The Eastern woodchuck
(Marmota monax) infected with the woodchuck hepa-
titis virus (WHV) has been used for studies of the patho-
genesis of chronic HBV infection and in the preclinical
evaluation of efficacy and safety of antiviral compounds
for the prevention of HBV disease sequelae, including
HCC. This animal model mimics many of the virological
and immunological response features observed in human
HBV infection [26] and has been predictive of human re-
sponses to antiviral drugs [27]. The woodchuck model has
been also used to test antitumor compounds for preven-
tion and treatment of HCC [28–31]. HCC develops and is
fatal in 100% of woodchucks that are chronically infected
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with WHV. The median time for HCC appearance in
woodchucks is 24 months of age, the median life expect-
ancy is 30 to 32 months, and after identification of HCC
the median survival time is six months, a situation similar
to patients with HCC [30, 32]. Furthermore, WHV-
induced HCC strongly resembles HBV-induced pri-
mary liver cancer in humans [30, 32–34]. Comparable
to the HCC development process in humans, liver tu-
mors in woodchucks obtain their malignancy in a
stepwise process. These distinct characteristics greatly
support the preclinical testing of new prophylactic
and therapeutic strategies against HBV-induced HCC
in woodchucks.
In the present study, antiviral and antitumor efficacy of
JVRS-100 was evaluated in chronic WHV carrier wood-
chucks with pre-existing liver tumors during intravenous
(IV) treatment for 12 weeks. Compared to placebo-treated
animals, JVRS-100 administration resulted in a reduction
of serum viral markers that was associated with the pre-
vention of new liver tumor formation but did not have an
apparent effect on established liver tumors.
Methods
Preparation of JVRS-100
JVRS-100 was manufactured by Juvaris BioTherapeutics,
Inc. (Pleasanton, CA). The compound was prepared by
mixing cationic lipid DOTIM (1-[2-(oleoyloxy)ethyl]-2-
oleyl-3-(2-hydroxyethyl)imidazolinium chloride) and
neutral lipid cholesterol with plasmid DNA (pMB75.6;
4,242 bp in length) in the presence of lactose followed
by lyophilization and storage at 2-8 °C. JVRS-100 was
reconstituted prior to use by the addition of sterile water
for injection for IV administration at the indicated
dosage.
Determination of JVRS-100 mediated immune activation
ELISA-based assays for the detection of woodchuck
cytokines and T cell surface markers in blood are not
available. For circumventing this limitation, real time
RT-PCR-based assays for the detection of mRNA expres-
sion of cytokines and T cell surface markers in wood-
chuck peripheral blood mononuclear cells (PBMCs) and
liver were applied as described [31, 35, 36]. Aliquots of
PBMCs or liver were lysed using the RNeasy Kit
(Qiagen) according to the manufacturer’s specifications
and total RNA isolated. RNA was then treated with
DNase I (Invitrogen) and reverse transcribed to comple-
mentary (c) DNA with MultiScribe Reverse Transcript-
ase (Applied Biosystems) using oligo(dT). Triplicates of
cDNA were amplified by real time PCR on a 7000 Real
Time PCR System instrument (Applied Biosystems)
using SYBR Green Master Mix (Applied Biosystems)
and woodchuck-specific primers for amplification of
interferon-alpha (IFN-α), interferon-gamma (IFN-γ),
tumor necrosis factor-alpha (TNF-α), IL-2, IL-6, IL-10,
IL-12, clusters of differentiation 4 and 8 (CD4 and CD8),
and forkhead box P3 (FoxP3) [36, 37]. Target gene expres-
sion was normalized via the expression of woodchuck β-
actin mRNA (PBMCs) or 18S rRNA (liver) [36, 38].
Transcription levels of woodchuck target genes were
determined by the formula 2ΔCt, where ΔCt indicates the
difference in the threshold cycle between housekeeping
and target gene expression. Results were represented as a
fold increase of the transcription level in PBMCs or liver
obtained from woodchucks following dosing with JVRS-
100 relative to animals administered vehicle.
Antiviral and antitumor efficacy study design
The animal protocol and all procedures involving wood-
chucks were approved by the Cornell University Institu-
tional Animal Care and Use Committee and adhered to
the national guidelines of the Animal Welfare Act, the
Guide for the Care and Use of Laboratory, and the
American Veterinary Medical Association. Twelve adult
woodchucks of either gender, approximately two years
of age, seropositive for WHV and with pre-existing liver
tumors were used for the evaluation of antiviral and
antitumor activity mediated by JVRS-100. These wood-
chucks were born to WHV-negative females, inoculated
at three days of age with a standardized inoculum contain-
ing WHV strain 7 (WHV7), and reared in the animal
facilities at Cornell University. The chronic WHV carrier
status of woodchucks at approximately two years after
birth was confirmed serologically by testing for the pres-
ence of WHV DNA, WHV surface antigen (WHsAg), and
antibodies against WHV core antigen, and for the absence
of antibodies against WHsAg (anti-WHs) [39]. Wood-
chucks for use had at least one hepatic tumor of approxi-
mately 1 cm or more in diameter within the left lateral
liver lobe as identified by elevated serum activity of
gamma-glutamyl transferase (GGT; i.e., > 10 IU/L) and by
hepatic ultrasound examination [30]. Characteristically
liver tumors of 1 cm or more in diameter are well differ-
entiated or moderately well differentiated trabecular
HCCs [30]. One or more ultrasound images were main-
tained as reference for post-treatment comparisons. The
woodchucks were then stratified as they entered the study
sequentially into either a JVRS-100 treatment group or a
vehicle-treated control group. The initial group of three
woodchucks was dosed IV with 100 μg JVRS-100/animal
every second week for 12 weeks starting at T0, while the
control group of three other woodchucks received IV ve-
hicle as placebo at the same time points. An additional
three woodchucks were dosed IV with 300 μg JVRS-100/
animal every second week for 12 weeks starting at T0,
while an additional three woodchucks received IV vehicle
as placebo at the same time points. For the analysis of
antiviral and antitumor effects mediated by JVRS-100, and
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for simplicity of data presentation, all six placebo-treated
animals were included in one group. This study design
allowed to compare two JVRS-100 dose groups (n = 3/
group) with one control group (n = 6).
As woodchucks entered the study (T0), animals were
anesthetized and weighed, and a blood sample was ob-
tained and used for serological testing, for determination
of serum WHV DNA loads, and for determinations of
clinical chemistry parameters and complete blood counts.
JVRS-100 or vehicle was then administered IV using the
sublingual vein. Additional blood samples were collected
biweekly. Additional ultrasound examinations were per-
formed every second week over a period of 24 weeks. At
the indicated time points, all woodchucks were anesthe-
tized, weighed, bled, the liver examined by ultrasound,
and JVRS-100 or vehicle administered IV. Hepatic expres-
sion of woodchuck cytokines and T cell surface markers
was determined in liver biopsy samples collected at pre-
treatment, during treatment (week 6), at the end of treat-
ment (week 12), and at the end of the study (week 24).
After the completion of the study, all woodchucks
were euthanized and complete post-mortem examina-
tions performed.
Determination of changes in the chronic WHV carrier
status of woodchucks
SerumWHV DNA was measured by two different methods
depending on concentration: (1) WHV DNA was
assayed by dot blot hybridization using three replicate
samples of undiluted serum and comparison to a stand-
ard dilution series of WHV recombinant DNA plasmid
(assay sensitivity, ≥ 1.0x107 WHV ge/ml; or (2) by real
time PCR assay of three replicate samples of WHV
DNA extracted from 200 μl of serum and comparison
to parallel PCR assays of 10-fold dilutions of the WHV
DNA plasmid standard (assay sensitivity, ≥ 1.0 × 103
WHV ge/ml) [39]. Levels of WHsAg and of anti-WHs
antibodies in serum were determined by ELISA using 1:50
dilutions of serum to insure detection of all markers under
saturating conditions [40]. Serum enzyme activities such
as GGT, sorbitol dehydrogenase (SDH), alanine amino-
transferase (ALT), aspartate aminotransferase (AST), and
alkaline phosphatase (ALP), and complete blood counts
were assayed as described [39].
Determination of changes in HCC status of woodchucks
The rate of tumor growth and echoic characteristics of
hepatic tumors present before and/or developing during
and following treatment with JVRS-100 or vehicle were
assessed by ultrasonography. During each ultrasound
examination three separate three-dimensional measure-
ments were performed, the diameter recorded, and one or
more images recorded digitally for retrospective analysis.
Tumor volumes and growth rates of woodchucks in all
groups were calculated and compared.
Tumor burden was assessed by examination of digital
pictures of the diaphragmatic and visceral surfaces of
the liver obtained during post-mortem examination
following euthanasia at the end of the study. The total
number of tumors and of all other hepatic neoplasms
present at necropsy was counted, the mean diameter of
each determined by direct caliper measurement, and the
total tumor volume (in cubic centimeters) of tumors
greater than 1 cm in diameter calculated. The antitumor
effect induced by JVRS-100 was then determined by
comparing the total number of tumors in the liver and
the total tumor volume in woodchucks treated with
JVRS-100 at two separate doses to the same parameters
of woodchucks that received vehicle-placebo.
Statistics
The antiviral and antitumor parameters were compared
between the groups of woodchucks using Student’s t-test.
P values of < 0.05 were considered statistically significant.
Results
Immune responsiveness of woodchucks with increasing
viral loads
For determining the dependency of responsiveness to
immune stimulation on serum WHV DNA, cytokine and
T cell surface marker mRNA expression was evaluated
following dosing of JVRS-100 in four age- and gender-
matched chronic WHV carrier woodchucks with low
(mean: 2.5 × 1010 genomic equivalents (ge)/ml) versus
high (mean: 6.0 × 1011 ge/ml) viral load. The working
hypothesis was that high viral load that is usually seen in
chronic WHV infection (approximately 100-fold higher
than the typical human viral load) results in immune sup-
pression to external immune stimuli. Woodchucks were
dosed IV once with JVRS-100 (concentration range: 50 to
100 μg/animal) and then evaluated for mRNA expression
of important antiviral cytokines, such as IFN-α, IFN-γ,
and TNF-alpha, and for T cell surface markers, such as
CD4 and CD8 in PBMCs obtained at eight hours post-
injection. FoxP3 expression was included in this analysis
for determining changes in regulatory T (Treg) cell func-
tion. The single dose of 50 to 100 μg/animal applied to
woodchucks was based on IV dosing in mice where it has
been established that 1 to 10 μg/animal elicited a robust
cytokine response [21]. Since interspecies differences in
the response to JVRS-100 are known (personnel commu-
nication; J. Fairman) and data on the use of this immunos-
timulant in woodchucks were lacking, it was decided to
start dosing at the low end of the activity range. Age- and
gender-matched control woodchucks with comparable
low or high viral load were dosed IV once with placebo
and the expression of cytokines and T cell surface markers
Fairman et al. BMC Cancer  (2017) 17:172 Page 4 of 11
also determined at eight hours post-injection. Relative to
placebo administration in control animals, the wood-
chucks with low serum viral load showed an increase in
the expression of all markers with the exception of FoxP3,
which was slightly down-regulated following administra-
tion of JVRS-100 (Fig. 1). In contrast, and again relative to
placebo administration in control animals, the wood-
chucks with high serum viral load demonstrated little
change in cytokine or T cell surface marker expression
(Fig. 1), suggesting a general unresponsiveness to stimula-
tion with JVRS-100 at the selected dose range. For verify-
ing the JVRS-100 mediated response in woodchucks with
low viremia with a broader panel of cytokines, and for
differentiating between TH1 and TH2 cellular immune
responses, four additional age-matched, female chronic
WHV carrier woodchucks with low serum WHV DNA
(mean: 1.3 × 1010 ge/ml) were dosed IV once with 100 μg
JVRS-100 and the expression of the above markers, in
addition to the cytokines IL-2, IL-6, IL-10, and IL-12, was
evaluated at eight hours post-injection (Fig. 2). Age- and
gender-matched control animals with comparable low
viral load were dosed IV once with placebo and the ex-
pression of all markers was also determined at eight hours
post-injection. Relative to placebo administration in
control animals, all woodchucks that received JVRS-100
demonstrated a marked upregulation of the expression of
T cell surface markers and of mainly TH1 cytokines, such
as IFN-α, IFN-γ, TNF-α, IL-2, and IL-12. Regarding TH2
cytokines, minimal changes were observed in the expres-
sion of IL-10, while IL-6 and the Treg marker FoxP3 were
slightly down-regulated. Considering the observed respon-
siveness in these animals that suggested a TH1 skew
toward cellular immune responses following JVRS-100
administration, the follow-on antiviral and antitumor
study was conducted in woodchucks which had low serum
WHV DNA of 2.0 × 1010 ge/ml on average at the start of
treatment, which is still higher but more comparable to
the viral load typically seen in HBV-infected patients.
In vivo antiviral and antitumor effects mediated by JVRS-
100 in chronic WHV infected woodchucks with HCC
Before woodchucks entered the study, all animals had
been confirmed as chronic WHV carriers based on the
presence of WHV DNA and WHsAg and absence of anti-
WHs in serum. All woodchucks had (sometimes highly)
elevated serum levels of GGT (range: 12–203 IU/L), which
is an oncogenic biomarker in this animal model and indi-
cative of pre-existing liver tumors that were also con-
firmed by ultrasonography. Animals presented with 1–3
tumors at this time and the average tumor size ranged be-
tween 0.93 and 5.03 cm in diameter. JVRS-100 or vehicle
was then administered IV at T0 using the sublingual vein
(Fig. 3). Administrations were repeated every 2 weeks
thereafter for a total of 12 weeks (i.e., 7 doses of JVRS-100
or vehicle placebo were given). After the end of treatment,
animals were followed for additional 12 weeks. Blood sam-
ple collection for serological testing and ultrasound exam-
inations for determinations of tumor growth and new
tumor formation were performed biweekly, while liver tis-
sues for expression analysis of cytokines and T cell surface
markers were collected at pre-treatment, and again at
weeks 6, 12 and 24 (Fig. 3).
Following an initial group of three woodchucks dosed
with 100 μg JVRS-100 and of three other woodchucks
administered vehicle as placebo control, an additional
three woodchucks were dosed with 300 μg JVRS-100
0.25
0.5
Fig. 1 Immune responsiveness of woodchucks with increasing viral loads following a single IV dose of JVRS-100. Fold increase in mRNA
expression of cytokines and T cell surface markers in peripheral blood following a single IV dose of JVRS-100 at a concentration of 50 or
100 μg/animal into woodchucks with low (n = 2) versus high (n = 2) serum WHV DNA loads. Results are presented as a change from the
transcription level observed in control woodchucks with comparable low (n = 2) or high (n = 2) viral loads following a single IV dose of
placebo. Vertical lines denote standard deviations
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and controlled by three other placebo-treated wood-
chucks. This study design allowed to compare two dose
groups (n = 3/group) with one control group (n = 6).
There were no flare reactions during or following treat-
ment with JVRS-100 as determined by the changes in
serum activity of liver enzymes, such as SDH, ALT, AST,
and ALP (data not shown). Occasionally, normalization of
ALP and AST levels, and in part also of ALT and GGT
levels, was observed during treatment with JVRS-100
mainly at the higher dose; however, most liver enzymes in-
cluding GGT rose again after the end of treatment.
Regarding antiviral effects, all woodchucks treated with
JVRS-100 demonstrated reductions in serum WHV DNA
and WHsAg during treatment. When normalized for the
differing amounts of initial viremia and antigenemia, there
was a steady decrease in the treated animals when com-
pared with the control animals, and the decline in WHV
DNA was more pronounced than for WHsAg (Fig. 4). In
addition, woodchucks treated with the higher dose of
JVRS-100 showed significant reductions (P < 0.05) in
serum WHV DNA (weeks 2, 4, 8–16, and 20–24) and
WHsAg (weeks 2–24) when the group mean was com-
pared to that of the control group. Less notable reductions
were observed for woodchucks treated with the lower
dose of JVRS-100 but the decline in serum WHV DNA
was statistically significant (P < 0.05) at week 10. Despite
these declines in viremia and antigenemia, none of the
JVRS-100 treated woodchucks demonstrated seroconver-
sion to anti-WHs antibodies (data not shown). Antiviral
effects were transient as serum WHV DNA and WHsAg
started to relapse during weeks 14–16 after the cessation
of JVRS-100 treatment, although levels of viremia and
antigenemia stayed below those of the control group dur-
ing most time points of the follow-up period.
Regarding antitumor effects, there was no difference
in the tumor burden as measured by the total volume of
pre-existing liver tumors in woodchucks during and fol-
lowing treatment with JVRS-100 at both doses when
compared to placebo-treated animals (data not shown),
suggesting that JVRS-100 based immunotherapy had no
apparent effect on already established tumors. However,
there was a difference in the formation of additional tu-
mors following initiation of treatment with JVRS-100 at
the high dose. As shown in Fig. 5, the cumulative mean
average number of new liver tumors detected in wood-
chucks was comparable (P > 0.05) between the six ani-
mals that received placebo and the three animals
administered the low dose of JVRS-100. This was in
clear contrast to the three woodchucks treated with the
0.25 
0.5 
Fig. 2 Immune responsiveness of woodchucks with low viral loads following a single IV dose of JVRS-100. Fold increase in mRNA expression of
cytokines and T cell surface markers in peripheral blood following a single IV dose of JVRS-100 at a concentration of 100 μg/animal into wood-
chucks with low serum WHV DNA load (n = 4). Results are presented as a change from the transcription level observed in control woodchucks
with comparable low viral load following a single IV dose of placebo (n = 4). Vertical lines denote standard deviations
Fig. 3 Experimental outline for IV administration of JVRS-100 in
woodchucks with pre-existing liver tumors for determining antiviral
and antitumor effects. CBC: Complete blood counts
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high dose of JVRS-100 in which new liver tumors did
not develop over the 24 weeks of the study as deter-
mined by ultrasound examination and as confirmed at
necropsy, suggesting that JVRS-100 at a well-tolerated
dose of 300 μg/animal mediated immune effects that
prevented tumor spread and metastasis. The prevention
of new liver tumors was significant (P < 0.05) from week
16 onward when the cumulative mean average number
was compared to woodchucks receiving JVRS-100 at the
lower dose of 100 μg/animal. Although the number of
animals in the treatment groups were limited, this find-
ing is highly unusual for this disease model in which
woodchucks with pre-existing liver tumors have a sur-
vival time of six months before they die or need to be
euthanized due to seizures known to be associated with
the development of terminal HCC. The above finding,
therefore, may present an important discovery for fur-
ther development of immunotherapy as an intervention
for HBV-induced HCC that need to be investigated in
more detail.
Regarding the expression of cytokines and T cell sur-
face markers in liver, woodchucks treated with the
higher dose of JVRS-100 demonstrated increases in CD4
and CD8 and in mainly TH1 cytokines such as IFN-α,
TNF-α, IL-2, and IL-12 during and following treatment
relative to control animals (Fig. 6). The expression of the
TH2 cytokine IL-10 was also increased as well as was the
expression of the Treg marker FoxP3 although to a lesser
degree. Since the magnitude and duration of expression
of CD4, CD8, IFN-α, TNF-α, and IL-12 was less pro-
nounced in woodchucks treated with the lower dose of
JVRS-100, the overall results suggest that administration
of JVRS-100 at an effective and safe dose activates an
antiviral and antitumor immunity that is mainly medi-
ated by the induction of TH1 immune responses in liver
and periphery and thereby blocks the conversion of
viral-induced chronic liver disease into HCC in vivo.
Discussion
The recent development of effective nucleos(t)ide analogs
with high barrier to viral resistance represents substantial
progress in the control of chronic HBV infection. How-
ever, treatment of chronic hepatitis B (CHB) is still
challenging as these direct acting antivirals do not target
the viral, covalently-closed circular (ccc) DNA molecule
within the nucleus of hepatocytes, which is representing
the HBV genome and that is utilized by the virus as a tem-
plate for synthesizing the pre-genomic RNA required for
replication [41]. Thus, although the levels of viremia (and
of antigenemia to varying degree) are strongly suppressed
by treatment with nucleos(t)ide analogs, low-level, re-
sidual viral replication persists and supports the mainten-
ance of immune tolerance to chronic HBV infection and
associated liver disease progression, including liver tumor
Fig. 4 Antiviral effects mediated by JVRS-100 in chronic WHV infected
woodchucks with HCC. Percentage change in serum WHV DNA (a)
and WHsAg (b) from pre-treatment level at T0 in woodchucks with
pre-existing liver tumors during and following IV treatment with JVRS-
100 at concentrations of 100 μg/animal (low dose; n = 3) or 300 μg/
animal (high dose; n = 3) or with vehicle (placebo; n = 6) for 12 weeks.
Vertical lines denote standard deviations
Fig. 5 Antitumor effects mediated by JVRS-100 in chronic WHV
infected woodchucks with HCC. Cumulative mean average number
of new liver tumors developed in woodchucks with pre-existing liver
cancer during and following IV treatment with JVRS-100 at
concentrations of 100 μg/animal (low dose; n = 3) or 300 μg/animal
(high dose; n = 3) or with vehicle (placebo; n = 6) for 12 weeks.
Vertical lines denote standard deviations
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formation and HCC. As recrudescence of viral replica-
tion is frequently observed following cessation of treat-
ment with nucleos(t)ide analogs [9], prolonged or even
lifelong therapy is needed to produce sustained control
of HBV infection. Unlike (pegylated) IFN-α, which has
inhibitory effects on HBV replication and transcription,
nucleos(t)ide analogs do not induce broad immunosti-
mulatory activity that facilitates immune clearance of
HBV-infected hepatocytes [42]. IFN-α has many immu-
nostimulatory properties such as activation of innate and
adaptive immune responses against HBV but its use as an
anti-HBV therapeutic is limited by the severe toxicity
observed in the majority of treated patients [43]. Thus,
continued development of new immunostimulatory com-
pounds against HBV is warranted that can mimic the ben-
efits of IFN-α without its toxicity. In the present study, the
antiviral and antitumor properties of JVRS-100, a potent
stimulant of innate immunity [17, 18, 20], were tested
in woodchucks with chronic WHV infection and pre-
existing liver tumors.
Chronic WHV infection in woodchucks closely repro-
duces the virological, immunological, and histopatho-
logical features observed in chronic HBV infection in
humans [26]. An important difference is that chronic
WHV infection is associated with a considerably higher
viral load which frequently exceeds 1010 ge/ml. In
human CHB, patients classified as being high viremic
have maximum HBV DNA serum concentrations of
approximately 108 ge/ml. These high levels of circulat-
ing WHV virions have been implicated in the impair-
ment of immune response in woodchucks, including
exhaustion of effector T cell function [44, 45], thereby
rendering chronic WHV infection into a disease condi-
tion that is extremely difficult to treat. As shown in the
present study, responsiveness to immune stimulation
with a single dose of JVRS-100 demonstrated a depend-
ency on viral load as only woodchucks with relatively
low viremia level had an increase in transcripts for anti-
viral cytokines and T cell surface markers in peripheral
blood (Fig. 1 and Fig. 2). In line with previous results in
WHV-naïve woodchucks [35] and other animal models
[17, 24], JVRS-100 administration to chronic WHV
carrier woodchucks changed the TH1/TH2 balance, with
an apparent TH1 skew toward cellular immune re-
sponses as suggested by the upregulated expression of
IFN-α, IFN-γ, TNF-α, IL-2, and IL-12 (Fig. 2).
Based on the above findings, chronic WHV carrier
woodchucks with low viremia were subsequently selected
for the antiviral and antitumor efficacy study (Fig. 3). Re-
peated administration of JVRS-100 for 12 weeks induced
marked but transient antiviral effects, including declines
in serum WHV DNA and WHsAg that were more pro-
nounced in woodchucks treated with the higher dose and
that stayed suppressed for most time points during the
follow-up period (Fig. 4). These findings in woodchucks
are in line with other studies demonstrating that immuno-
therapy in the setting of low viremia is antiviral efficacious
whereas in the setting of high viremia, the same thera-
peutic approach leads to an activation of immunosuppres-
sive mechanisms thereby abolishing the antiviral effect of
treatment. For example, high viral and/or antigen load
have been implicated to be an important cause of T cell
hyporesponsiveness to HBV antigens [46, 47]. In addition,
high viremia has been shown to be a main factor that
negatively predicts antiviral response to IFN-α treatment
in patients with chronic HBV infection [48]. In wood-
chucks, hepatic delivery of the immunostimulatory cyto-
kines IL-12 or IFN-α fused to apolipoprotein A-I by viral
vectors resulted in marked antiviral effects [36, 49], but
only in animals with relatively low viral load (below 1010
ge/ml) which was not observed in animals with high
viremia (≥1011 ge/ml). Furthermore, woodchucks with
response to IL-12 therapy developed cellular immune





Fig. 6 Intrahepatic expression of cytokines and T cell surface markers
mediated by JVRS-100 in chronic WHV infected woodchucks with HCC.
Fold increase in mRNA expression of cytokines and T cell surface
markers in liver of woodchucks with pre-existing liver cancer during
and following IV treatment with JVRS-100 at concentrations of 100 μg/
animal (low dose; n = 3) (a) or 300 μg/animal (high dose; n = 3) (b).
Results are presented as a change from the transcription level observed
in control woodchucks during and following IV treatment with vehicle
(placebo; n = 6). Vertical lines denote standard deviations
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Treg cells such as FoxP3-expressing cells [36]. Contrary,
high-viremic woodchucks unresponsive to IL-12 therapy
had a significant increase in FoxP3 expression and failed
to develop WHV-specific cellular responses [36]. In regard
to Treg cells, JVRS-100 in the present study was found
to have little impact on the expression of FoxP3 at eight
hours post-injection, and a single dose administration
of JVRS-100 did not result in apparent expression dif-
ferences for FoxP3 in the setting of low versus high
viremia (Fig. 1 and Fig. 2). Other molecules or cyto-
kines with inhibitory functions such as programmed
death 1 (PD-1), its ligand (PD-L1), and transforming
growth factor beta (TGF-β) that were not tested in the
present study may play a role in the observed unre-
sponsiveness of high-viremic woodchucks to JVRS-100.
Overall, the peripheral blood system and the liver of
woodchucks with high viremia appear to present a highly
suppressive environment that can counter-regulate anti-
viral effects induced by immunotherapy with broad-acting
compounds such as IL-12 [50], IFN-α [49] or JVRS-100.
This appears opposite to immunotherapy with specific-
acting compounds such as the small molecule TLR7 agon-
ist GS9620 and the viral sensor protein activator SB 9200
that induced pronounced and sometimes sustained anti-
viral effects in woodchucks with high viremia [38, 51, 52].
Thus, it is important to note for further immunotherapeu-
tic development in the woodchuck model that animals
with relatively low viremia responded to JVRS-100,
whereas animals with relatively high viremia appeared
unresponsive. This may have important implications in
the selection of potential patients with CHB for treatment
with JVRS-100 in a future clinical trial.
Aside from the immunostimulatory activity in the set-
ting of low versus high viremia, the antiviral response
induced by JVRS-100 in the present study (Fig. 4) was
in the range of those of nucleos(t)ide analogs previously
evaluated in the woodchuck model. The magnitude of
viral load reduction with JVRS-100, especially at the
high dose, was comparable to lamivudine and emtricita-
bine after administration for 12 weeks [39]. Common
for these compounds but somewhat different to JVRS-100
was the immediate rebound of WHV markers following
cessation of treatment. Comparable to JVRS-100, these
nucleos(t)ide analogs also induced minor, transient in-
creases in liver enzymes during treatment, and before
serum activity of AST, ALP and/or ALT became normal-
ized. As elevations in these liver enzymes noted during
JVRS-100 treatment at week 8 were temporally associated
with the reductions in serum WHV DNA (and WHsAg),
their rise may indicate immune-mediated viral clearance
of infected hepatocytes by CTLs and NK cells, as also
observed in other studies for this compound [20–22]. As
liver enzyme activity was transient and became normal-
ized at the end of treatment, this may further indicate that
other, non-cytolytic mechanism(s) contributed to the sup-
pression of WHV replication. The data in chronic WHV
carrier woodchucks is also in agreement with the demon-
strated efficacy of JVRS-100 in HBV transgenic mice. In a
dose-ranging study in this animal model, IV administra-
tion of JVRS-100 (0.005 to 5 μg/mouse) on days 1, 7, and
13 resulted in significant reduction in liver HBV DNA
after 14 days and the achieved antiviral effect at higher
doses was comparable to that of adefovir [53]. Suppression
of hepatic HBV DNA in mice by JVRS-100 was associated
with significantly increased cytokine levels in liver and
serum, including the TH1 cytokine IL-12. This result was
confirmed by the current study since elevated transcript
levels of CD4 and CD8 and of mainly TH1 cytokines (IFN-
α, TNF-α, IL-2, and IL-12) were observed in woodchucks
that were treated with the higher dose of JVRS-100 and
which demonstrated more pronounced antiviral and anti-
tumor effects when compared to animals treated with the
lower dose (Fig. 6). However, expression of IL-10, an im-
munosuppressive cytokine produced by Treg cells and
various other cells, was markedly upregulated by the high
dose of JVRS-100, which was consistent with the increase
in FoxP3 expression.
Treatment of chronic WHV carrier woodchucks with-
out pre-existing liver tumors at pre-treatment with
nucleos(t)ide analogs and immunostimulators has been
shown to delay or even prevent the onset of HCC de-
velopment [30, 51]. The conclusion from these studies
is that prolonged suppression of viral replication results
in less liver injury and cellular damage thereby defer-
ring transformation of altered hepatocytes into tumors.
The effect of the above treatment on pre-existing liver
tumors, however, is unknown as drug efficacy studies in
the woodchuck are typically initiated in HCC-free ani-
mals as determined by ultrasonography and low GGT
levels. Studies which tested antitumor treatment of pre-
existing liver tumors in woodchucks by delivery of
murine IL-12, alone or in combination with the costi-
mulatory factor B7.1, demonstrated partial remission
based on transient changes in tumor growth [29, 31].
However, these studies did not evaluate if formation of
new tumors was abolished as observed in the present
study (Fig. 5). The antitumor response in woodchucks
of the above studies [29, 31] as well as in the current
study was associated with a general activation of cellu-
lar and/or hepatic immune responses, including the in-
duction of TH1 cytokines and T cell markers. As this
response is comparable to that mediated by JVRS-100
in another animal model of cancer [25] and in wood-
chucks with low viremia and/or pre-existing liver
tumors (Fig. 1, Fig. 2 and Fig. 6), it is tempting to
speculate that dosing with JVRS-100 at an increased
frequency and/or at a higher dose may have resulted in
direct antitumor effects that needs to be explored in a
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future study. However, the finding that JVRS-100 at a
high dose mediates an effect on the formation of new
tumors has not been demonstrated for other com-
pounds in animal models of virus-induced HCC.
Conclusions
Since treatment with JVRS-100 was effective and safe in
preventing new liver tumor formation in woodchucks
with chronic WHV infection and established HCC, it
deserves consideration as a potential therapy for patients
with CHB, especially in patients who have low HBV load
or who are at a higher risk for development of HBV-
induced HCC.
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